Improving outcomes for patients with metastatic NSCLC with immunotherapy

preview_player
Показать описание
Mirjana Rajer, MD, PhD, Institute of Oncology Ljubljana, Ljubljana, Slovenia, talks on the introduction of immunotherapy into the treatment landscape for patients with metastatic non-small cell lung cancer (NSCLC), and how this has improved patient outcomes. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
Рекомендации по теме